Market Overview

Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference


Impax Pharmaceuticals,the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64^th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28. IPX066 is an investigational, patented extended release capsule formulation of carbidopa-levodopa intended for the treatment of idiopathic Parkinson's disease. IPX066 is being developed in collaboration with GlaxoSmithKline for territories countries outside the U.S. and Taiwan.

Posted-In: News FDA


Related Articles (IPXL)

View Comments and Join the Discussion!

Partner Center